Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca discontinues Elavil

Executive Summary

AstraZeneca has discontinued its antidepressant Elavil (amitriptyline). The injection form is no longer available and the tablet inventory is expected to be depleted by the end of the year. The drug, which was manufactured by Merck, was cited for GMP problems in 2000 (1"The Pink Sheet" July 17, 2000, p. 24)...

You may also be interested in...

Vioxx GMP Violations Cited In FDA Warning Letter Spur Merck Retraining

Inadequate sampling, testing, investigation and documentation of Merck's Vioxx (rofecoxib) lots are among good manufacturing practice violations cited in a June 27 FDA warning letter.

QUOTED. 28 January 2020. Steven Falowski.

Abbott is encouraged by results from two studies of its Proclaim XR neurostimulation system for chronic pain, presented at the annual North American Neuromodulation Society (NANS) meeting in Las Vegas. See what Steven Falowski of Neurosurgical Associates of Lancester in Pennsylvania said about it here.

Japan Phase III Failure To End Mono Opdivo Hopes In Ovarian Cancer?

While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.

Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts